SCHEMBL3205795

SCHEMBL3205795

CCN(NC(=O)OC)C(=O)c1cc(Br)cc(Br)c1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.34
GFER P55789 1/20 0.34
CYP1A2 P05177 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CYP2D6 P10635 1/20 0.34
DRD1 P21728 1/20 0.34
ACHE P22303 1/20 0.34
PTGS1 P23219 1/20 0.34
DRD3 P35462 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 2/20 0.31
HPGD P15428 2/20 0.31
AKR1C4 P17516 1/20 0.30
AKR1C3 P42330 1/20 0.30
AKR1C2 P52895 1/20 0.30
AKR1C1 Q04828 1/20 0.30
MAPT P10636 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13489631 0.88 HSD17B10 (0.36) HSD17B10LMNAGFERCYP1A2HTR1A
SCHEMBL13541671 0.87 HSD17B10 (0.38) HSD17B10CYP1A2HTR1AADRA2ACYP2D6
SCHEMBL11983653 0.85 HSD17B10 (0.36) HSD17B10KDM4E
SCHEMBL3214512 0.82 HSD17B10 (0.39) HSD17B10LMNACYP1A2CYP2D6PTGS1
SCHEMBL3221115 0.79 CYP1A2 (0.36) HSD17B10LMNAGFERCYP1A2HTR1A
SCHEMBL11983650 0.78 HSD17B10 (0.38) HSD17B10LMNAGFERCYP1A2HTR1A
SCHEMBL10696103 0.77 LMNA (0.49) HSD17B10LMNAGFERALDH1A1HPGD
SCHEMBL639209 0.76 LMNA (0.39) HSD17B10LMNAGFERCYP1A2HTR1A
SCHEMBL13490119 0.73 CYP1A2 (0.34) HSD17B10LMNAGFERCYP1A2HTR1A
SCHEMBL13490105 0.73 HSD17B10 (0.33) HSD17B10LMNAGFERCYP1A2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785646-B2 Process for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-07-22 US disclosed
US-8541613-B2 Process for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-09-24 US disclosed
US-8501951-B2 Process for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-08-06 US disclosed
US-20130131348-A1 PROCESS FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-05-23 US disclosed
US-20130131371-A1 PROCESS FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-05-23 US disclosed
EP-2143721-B1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME SUMITOMO CHEMICAL CO (JP) 2012-08-15 EP disclosed
US-8119811-B2 Method for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-21 US disclosed
US-8119811-B2 Method for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-21 US disclosed
US-20100113794-A1 METHOD FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-06 US disclosed
US-20100113794-A1 METHOD FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-06 US disclosed
US-20100048640-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2143721-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-13 EP disclosed
EP-2143721-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131371-A1 PROCESS FOR PRODUCING AMIDE COMPOUND C9, F3, C5 HSD17B10 1616/4885LMNA 4146/4885GFER 1255/4885
US-20100048640-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME CYC1, L3MBTL1, CBR3 HSD17B10 2530/4885LMNA 3916/4885GFER 1137/4885
US-20130131348-A1 PROCESS FOR PRODUCING AMIDE COMPOUND C9, F3, C5 HSD17B10 1616/4885LMNA 4146/4885GFER 1255/4885
US-20100113794-A1 METHOD FOR PRODUCING AMIDE COMPOUND CBR3, AOX1, AOC2 HSD17B10 499/4885LMNA 2993/4885GFER 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.